These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 32076118)

  • 1. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications.
    Singh S; Ahmed D; Dolatshad H; Tatwavedi D; Schulze U; Sanchi A; Ryley S; Dhir A; Carpenter L; Watt SM; Roberts DJ; Abdel-Aal AM; Sayed SK; Mohamed SA; Schuh A; Vyas P; Killick S; Kotini AG; Papapetrou EP; Wiseman DH; Pellagatti A; Boultwood J
    Leukemia; 2020 Sep; 34(9):2525-2530. PubMed ID: 32076118
    [No Abstract]   [Full Text] [Related]  

  • 2. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation.
    Rombaut D; Lefèvre C; Rached T; Bondu S; Letessier A; Mangione RM; Farhat B; Lesieur-Pasquier A; Castillo-Guzman D; Boussaid I; Friedrich C; Tourville A; De Carvalho M; Levavasseur F; Leduc M; Le Gall M; Battault S; Temple M; Houy A; Bouscary D; Willems L; Park S; Raynaud S; Cluzeau T; Clappier E; Fenaux P; Adès L; Margueron R; Wassef M; Alsafadi S; Chapuis N; Kosmider O; Solary E; Constantinou A; Stern MH; Droin N; Palancade B; Miotto B; Chédin F; Fontenay M
    Nat Commun; 2024 Apr; 15(1):3016. PubMed ID: 38589367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
    Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
    Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alteration of SF3B1 and SRSF2 Genes in Myelodysplastic Syndromes Patients in Upper Northern Thailand.
    Yimpak P; Tantiworawit A; Rattanathammethee T; Angsuchawan S; Laowatthanapong S; Tasuya W; Bumroongkit K
    Asian Pac J Cancer Prev; 2019 Apr; 20(4):1215-1221. PubMed ID: 31030497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium Analysis.
    Migdady Y; Barnard J; Al Ali N; Steensma DP; DeZern A; Roboz G; Garcia-Manero G; Sekeres MA; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):528-532. PubMed ID: 29937400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.
    Stengel A; Kern W; Meggendorfer M; Haferlach T; Haferlach C
    Leukemia; 2017 Sep; 31(9):1995-1997. PubMed ID: 28592886
    [No Abstract]   [Full Text] [Related]  

  • 7. Clonal shifts in MDS - from SF3B1 to EZH2.
    Barbosa Ribeiro A; Coucelo M; Tenreiro R; Simões AT; Marques G; Ribeiro L; Cortesão E; Sarmento-Ribeiro AB
    Leuk Lymphoma; 2018 Dec; 59(12):2994-2997. PubMed ID: 29616853
    [No Abstract]   [Full Text] [Related]  

  • 8. Altered splicing and cytoplasmic levels of tRNA synthetases in SF3B1-mutant myelodysplastic syndromes as a therapeutic vulnerability.
    Liberante FG; Lappin K; Barros EM; Vohhodina J; Grebien F; Savage KI; Mills KI
    Sci Rep; 2019 Feb; 9(1):2678. PubMed ID: 30804405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Frequency of SF3B1 Mutations in Thai Patients with Myelodysplastic Syndrome.
    Rujirachaivej P; Siriboonpiputtana T; Rerkamnuaychoke B; Magmuang S; Chareonsirisuthigul T; Boonsakan P; Petvises S; Sirirat T; Niparuck P; Chuncharunee S
    Asian Pac J Cancer Prev; 2018 Jul; 19(7):1825-1831. PubMed ID: 30049194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower-risk myelodysplastic syndromes.
    Patel JL; Abedi M; Cogle CR; Erba HP; Foucar K; Garcia-Manero G; Grinblatt DL; Komrokji RS; Kurtin SE; Maciejewski JP; Pollyea DA; Revicki DA; Roboz GJ; Savona MR; Scott BL; Sekeres MA; Steensma DP; Thompson MA; Dawn Flick E; Kiselev P; Louis CU; Nifenecker M; Swern AS; George TI
    Int J Lab Hematol; 2021 Jun; 43(3):426-432. PubMed ID: 33220019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of SF3B1/DNMT3A Comutations With DNMT3A or SF3B1 Mutation Alone in Myelodysplastic Syndrome and Clonal Cytopenia of Undetermined Significance.
    Song J; Hussaini M; Qin D; Zhang X; Shao H; Zhang L; Gajzer D; Basra P; Moscinski L; Zhang H
    Am J Clin Pathol; 2020 Jun; 154(1):48-56. PubMed ID: 32112088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.
    Venable ER; Chen D; Chen CP; Bessonen KR; Nguyen PL; Oliveira JL; Reichard KK; Hoyer JD; Althoff SD; Roh DJ; Miller MA; Begna K; Patnaik MM; Litzow MR; Al-Kali A; Viswanatha DS; He R
    Am J Clin Pathol; 2021 Sep; 156(4):679-690. PubMed ID: 33978189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A variant erythroferrone disrupts iron homeostasis in
    Bondu S; Alary AS; Lefèvre C; Houy A; Jung G; Lefebvre T; Rombaut D; Boussaid I; Bousta A; Guillonneau F; Perrier P; Alsafadi S; Wassef M; Margueron R; Rousseau A; Droin N; Cagnard N; Kaltenbach S; Winter S; Kubasch AS; Bouscary D; Santini V; Toma A; Hunault M; Stamatoullas A; Gyan E; Cluzeau T; Platzbecker U; Adès L; Puy H; Stern MH; Karim Z; Mayeux P; Nemeth E; Park S; Ganz T; Kautz L; Kosmider O; Fontenay M
    Sci Transl Med; 2019 Jul; 11(500):. PubMed ID: 31292266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells.
    Pollyea DA; Kim HM; Stevens BM; Lee FF; Harris C; Hedin BR; Knapp JR; O'Connor BP; Jordan CT; Pietras EM; Tan AC; Alper S
    J Leukoc Biol; 2021 Jul; 110(1):197-205. PubMed ID: 33155727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Splicing modulators impair DNA damage response and induce killing of cohesin-mutant MDS and AML.
    Wheeler EC; Martin BJE; Doyle WC; Neaher S; Conway CA; Pitton CN; Gorelov RA; Donahue M; Jann JC; Abdel-Wahab O; Taylor J; Seiler M; Buonamici S; Pikman Y; Garcia JS; Belizaire R; Adelman K; Tothova Z
    Sci Transl Med; 2024 Jan; 16(728):eade2774. PubMed ID: 38170787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes.
    Komrokji R; Volpe V; Chan O; Al Ali N; Swoboda D; Kuykendall A; Padron E; Sallman DA
    Blood; 2021 Sep; 138(11):989-992. PubMed ID: 34036300
    [No Abstract]   [Full Text] [Related]  

  • 18. Prognostic significance of SF3B1 mutations in patients with myelodysplastic syndromes: A meta-analysis.
    Jafari PA; Sadeghian MH; Miri HH; Sadeghi R; Bagheri R; Lavasani S; Souri S
    Crit Rev Oncol Hematol; 2020 Jan; 145():102832. PubMed ID: 31812130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
    Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
    Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatic
    Foy A; McMullin MF
    J Clin Pathol; 2019 Nov; 72(11):778-782. PubMed ID: 31473630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.